Trial Profile

First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 25 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Methotrexate (Primary) ; Mycophenolate mofetil (Primary) ; Prednisolone; Prednisone
Indications Anterior uveitis; Intermediate uveitis; Panuveitis; Posterior uveitis; Uveitis
Focus Therapeutic Use
Acronyms FAST

Most Recent Events

01 Feb 2025 Results evaluating baseline macular morphologic features on optical coherence tomography and visual outcomes in patients with Vogt-Koyanagi-Harada Disease published in the Ocular Immunology and Inflammation.
17 Sep 2019 New trial record
10 Sep 2019 Primary endpoint of Treatment Success has not been met according to results published in the JAMA: the Journal of the American Medical Association.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com